| Project/Area Number |
15K14955
|
|---|
| Research Category |
Grant-in-Aid for Challenging Exploratory Research
|
| Allocation Type | Multi-year Fund |
|---|
| Research Field |
Biological pharmacy
|
|---|
| Research Institution | Chiba University |
|---|
Principal Investigator |
|
|---|
| Co-Investigator(Renkei-kenkyūsha) |
HIRAOKA Nobuyoshi 国立がん研究センター, ユニット長 (40276217)
HIRAKAWA Jotaro 千葉大学, 大学院薬学研究院, 助教 (30609160)
|
|---|
| Project Period (FY) |
2015-04-01 – 2018-03-31
|
| Project Status |
Completed (Fiscal Year 2017)
|
| Budget Amount *help |
¥3,640,000 (Direct Cost: ¥2,800,000、Indirect Cost: ¥840,000)
Fiscal Year 2016: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
Fiscal Year 2015: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
|
|---|
| Keywords | 抗糖鎖抗体 / シアリルルイスX / 大腸がん / がん転移 / バイオマーカー / 薬学 / 免疫学 / 糖鎖 / がん / 病理学 / フコース転移酵素 / セレクチン |
|---|
| Outline of Final Research Achievements |
In this study, we examined the possibility of our newly generated anti-carbohydrate antibodies as tumor biomarkers as well as the function of glycans in tumor metastasis. We first performed immunohistochemical analysis and found that F2 antibody-reactive sialyl Lewis X carbohydrate antigen is expressed in more than 90% of the colon carcinoma tissues. We also established an assay system to efficiently detect a carbohydrate biomarker, sialyl Lewis X, and determined the function of this carbohydrate antigen in tumor metastasis. It is expected that the results of the present study should be useful for the early diagnosis and treatment of tumors.
|
